Fulcrum Therapeutics (FULC) Cash & Equivalents (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash & Equivalents data on file, last reported at $50.3 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 19.16% year-over-year to $50.3 million in Q1 2026; TTM through Mar 2026 was $50.3 million, a 19.16% increase from a year earlier, with the FY2025 full-year figure at $197.5 million, down 18.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $50.3 million, down from $197.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for FULC reached as high as $241.0 million in Q4 2024 and fell as low as $30.1 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $89.8 million across 5 years, with a median of $47.1 million in 2025.
• Across the five-year window, Cash & Equivalents tumbled 66.93% in 2022 and jumped 573.03% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $35.1 million in 2022, then soared by 573.03% to $236.2 million in 2023, then grew by 2.03% to $241.0 million in 2024, then retreated by 18.04% to $197.5 million in 2025, then slumped by 74.56% to $50.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $50.3 million in Q1 2026, $197.5 million in Q4 2025, and $47.1 million in Q3 2025.